- Home
- LITM vs RLMD Comparison
LITM vs RLMD Comparison
Compare LITM & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LITM
- RLMD
- Stock Information
- Founded
- LITM 2018
- RLMD 2004
- Country
- LITM Canada
- RLMD United States
- Employees
- LITM N/A
- RLMD N/A
- Industry
- LITM Other Metals and Minerals
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- LITM Basic Materials
- RLMD Health Care
- Exchange
- LITM Nasdaq
- RLMD Nasdaq
- Market Cap
- LITM 26.7M
- RLMD 22.0M
- IPO Year
- LITM 2021
- RLMD N/A
- Fundamental
- Price
- LITM $3.59
- RLMD $0.61
- Analyst Decision
- LITM
- RLMD Buy
- Analyst Count
- LITM 0
- RLMD 3
- Target Price
- LITM N/A
- RLMD $5.00
- AVG Volume (30 Days)
- LITM 401.4K
- RLMD 439.6K
- Earning Date
- LITM 04-10-2025
- RLMD 08-06-2025
- Dividend Yield
- LITM N/A
- RLMD N/A
- EPS Growth
- LITM N/A
- RLMD N/A
- EPS
- LITM N/A
- RLMD N/A
- Revenue
- LITM N/A
- RLMD N/A
- Revenue This Year
- LITM N/A
- RLMD N/A
- Revenue Next Year
- LITM N/A
- RLMD N/A
- P/E Ratio
- LITM N/A
- RLMD N/A
- Revenue Growth
- LITM N/A
- RLMD N/A
- 52 Week Low
- LITM $1.98
- RLMD $0.24
- 52 Week High
- LITM $24.44
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- LITM 45.31
- RLMD 47.24
- Support Level
- LITM $3.25
- RLMD $0.67
- Resistance Level
- LITM $3.71
- RLMD $0.74
- Average True Range (ATR)
- LITM 0.26
- RLMD 0.07
- MACD
- LITM 0.04
- RLMD -0.03
- Stochastic Oscillator
- LITM 29.01
- RLMD 25.79
About LITM Snow Lake Resources Ltd.
Snow Lake Resources Ltd is a Canadian clean energy exploration company with a world-wide portfolio of clean energy mineral projects comprised of two uranium projects and two hard rock lithium projects. Its Projects include: The Black Lake Uranium Project, the Engo Valley Uranium Project, The Shatford Lake Project, and the Snow Lake Lithium Project.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.